PureIMS, a Roden, Netherlands-based pharmaceutical company, raised an undisclosed amount in funding.
New investor Boost-UP Foundation has joined current shareholders (CardusoCapital, IMDS Medical Devices and LinesBridge Pharma Group) in this round.
The company intends to use the funds to develop lead program Levodopa Cyclops™ for US and EEA marketing.
Led by CEO Jaap Wieling, PureIMS holds the licensing rights to Cyclops, a patient-focused dry powder inhaler for rapid and controlled drug delivery, pre-filled and single use, ensuring one dose delivery and onset of action. The inhaler is an alternative to a wide range of oral and parenteral dosage forms for pulmonary, systemic and rescue indications. The company recently concluded collaboration agreements for the application of Cyclops in the development of therapies for NTM and IPF and for COVID-19 vaccination.
In addition to partnering programs, PureIMS has a clinical stage in-house pipeline also open to outlicensing; lead programs are Cyclops™ inhalers for levodopa (PD), epinephrine (anaphylaxis) and colistin (CF and NCFB).
FinSMEs
04/04/2023